While the number of microbiome-focused products and investments rises, the science remains in a nascent stage, and expectations for the industry may be ahead of reality, according to speakers at a Bard College symposium on Thursday. Martha Carlin, CEO and co-founder of microbiome R&D company The BioCollective, says that there is still a lot of […]

To read the full article

OR